samedan logo
 
 
 
spacer
home > ebr > winter 2003 > killer apps for killer diseases
PUBLICATIONS
European Biopharmaceutical Review

Killer Apps for Killer Diseases

According to the Organization for Economic Co-Operation and Development, more than 17 million people die of infectious disease each year. Indeed, within the last three decades, no fewer than 30 new communicable diseases have emerged for which no effective treatment exists. Just about every major antibiotic has shown the evolution of resistance within three years of introduction, which means that the list of unmet needs is growing. Can biotechnology buck the trend?

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By G Steven Burrill, CEO of Burrill & Company

G Steven Burrill is CEO of Burrill & Company, a San Francisco-based life sciences merchant bank. Mr Burrill currently serves on eight Boards of Directors including DepoMed (Amex: DMI) and Third Wave Technologies (NASDAQ: TWTI), and is Chairman of the Boards of Pyxis Genomics and Paradigm Genetics (NASDAQ: PDGM). Prior to founding Burrill & Company in 1994, he spent 28 years with Ernst & Young directing and co-ordinating the firm's services to clients in the biotechnology, life sciences, high technology and manufacturing industries worldwide.

spacer
G Steven Burrill
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Over 300 Clinical Studies Benefit from CluePoints COVID-19 Risk Management Support

CluePoints, the premier provider of Risk-Based Study Execution (RBx) and Data Quality Oversight Software for clinical trials, today announced the success of its complimentary COVID-19 risk management package alongside comprehensive support for COVID-19 affected trials.
More info >>

White Papers

The Importance of Critical Temperatures in the Freeze Drying of Pharmaceutical Products

Biopharma Group

Every formulation has a critical temperature, below which it should be cooled for complete solidification and maintained below during primary drying in order to prevent processing defects. To design a freeze drying cycle on a rational basis such information should be identified.
More info >>

 
Industry Events

CPhI Festival of Pharma

5-16 October 2020, Virtual

A virtual gathering for the pharmaceutical industry, the CPhI Festival of Pharma has been created to fill the gap left by in-person events at a time when travel and gatherings are off the cards.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement